blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3054952

EP3054952 - COMBINATIONS OF HISTONE DEACETYLASE 6 INHIBITORS AND THE HER2 INHIBITOR LAPATINIB FOR USE IN THE TREATMENT OF BREAST CANCER [Right-click to bookmark this link]
Former [2016/33]COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS
[2022/15]
StatusNo opposition filed within time limit
Status updated on  01.09.2023
Database last updated on 18.09.2024
FormerThe patent has been granted
Status updated on  23.09.2022
FormerGrant of patent is intended
Status updated on  28.04.2022
FormerExamination is in progress
Status updated on  19.02.2019
Most recent event   Tooltip07.06.2024Lapse of the patent in a contracting state
New state(s): MC		published on 10.07.2024  [2024/28]
Applicant(s)For all designated states
Acetylon Pharmaceuticals, Inc.
70 Fargo Street, Suite 205
Boston, MA 02210 / US
[2016/33]
Inventor(s)01 / TAMANG, David Lee
140 Hillside Road 3
Watertown, MA 02472 / US
02 / YANG, Min
8 North Street
Newton, MA 02459 / US
03 / JONES, Simon S.
46 Westcott Road
Harvard, MA 01451 / US
 [2016/33]
Representative(s)Boult Wade Tennant LLP
Salisbury Square House
8 Salisbury Square
London EC4Y 8AP / GB
[2022/43]
Former [2016/33]Boult Wade Tennant
Verulam Gardens
70 Gray's Inn Road
London WC1X 8BT / GB
Application number, filing date14851657.806.10.2014
[2016/33]
WO2014US59238
Priority number, dateUS201361888207P08.10.2013         Original published format: US 201361888207 P
[2016/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015054099
Date:16.04.2015
Language:EN
[2015/15]
Type: A1 Application with search report 
No.:EP3054952
Date:17.08.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 16.04.2015 takes the place of the publication of the European patent application.
[2016/33]
Type: B1 Patent specification 
No.:EP3054952
Date:26.10.2022
Language:EN
[2022/43]
Search report(s)International search report - published on:RU16.04.2015
(Supplementary) European search report - dispatched on:EP14.03.2017
ClassificationIPC:A61K31/505, A61K31/517, A61K31/519, A61K31/52, A61K47/00, A61P35/00, A61K45/06, A61K31/5377, C07D239/42
[2017/15]
CPC:
A61K31/505 (EP,US); A61K31/517 (EP,US); A61K31/519 (EP,US);
A61K31/5377 (EP,US); A61K45/06 (EP,US); A61P35/00 (EP);
A61P43/00 (EP); C07D239/42 (EP,US) (-)
C-Set:
A61K31/505, A61K2300/00 (EP,US);
A61K31/517, A61K2300/00 (US,EP);
A61K31/519, A61K2300/00 (US,EP);
A61K31/5377, A61K2300/00 (US,EP)
Former IPC [2016/33]A61K31/505, A61K31/517, A61K31/519, A61K31/52, A61K47/00, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/33]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:KOMBINATIONEN VON HISTONDEACETYLASE 6 INHIBITOREN UND DEM HER2-INHIBITOR LAPATINIB ZUR BEHANDLUNG VON BRUSTKREBS[2022/17]
English:COMBINATIONS OF HISTONE DEACETYLASE 6 INHIBITORS AND THE HER2 INHIBITOR LAPATINIB FOR USE IN THE TREATMENT OF BREAST CANCER[2022/15]
French:COMBINAISONS D'INHIBITEURS D'HISTONE DÉSACÉTYLASE 6 ET DE L'INHIBITEUR D'HER2 LAPATINIB POUR LE TRAITEMENT DU CANCER DU SEIN[2022/17]
Former [2016/33]KOMBINATIONEN VON HISTONDEACETYLASEINHIBITOREN UND ENTWEDER HER2-INHIBITOREN ODER PI3K-INHIBITOREN
Former [2016/33]COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS
Former [2016/33]COMBINAISONS D'INHIBITEURS D'HISTONE DÉSACÉTYLASE ET D'INHIBITEURS D'HER2 OU DE PI3K
Entry into regional phase21.04.2016National basic fee paid 
21.04.2016Search fee paid 
21.04.2016Designation fee(s) paid 
21.04.2016Examination fee paid 
Examination procedure21.04.2016Examination requested  [2016/33]
03.10.2017Amendment by applicant (claims and/or description)
22.02.2019Despatch of a communication from the examining division (Time limit: M06)
05.12.2019Reply to a communication from the examining division
03.06.2020Despatch of a communication from the examining division (Time limit: M06)
20.01.2021Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
15.03.2021Reply to a communication from the examining division
28.04.2022Communication of intention to grant the patent
01.09.2022Fee for grant paid
01.09.2022Fee for publishing/printing paid
01.09.2022Receipt of the translation of the claim(s)
Opposition(s)27.07.2023No opposition filed within time limit [2023/40]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
15.03.2021Request for further processing filed
15.03.2021Full payment received (date of receipt of payment)
Request granted
24.03.2021Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
05.12.2019Request for further processing filed
05.12.2019Full payment received (date of receipt of payment)
Request granted
13.12.2019Decision despatched
Fees paidRenewal fee
11.10.2016Renewal fee patent year 03
27.10.2017Renewal fee patent year 04
29.10.2018Renewal fee patent year 05
28.10.2019Renewal fee patent year 06
14.10.2020Renewal fee patent year 07
29.09.2021Renewal fee patent year 08
15.09.2022Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL26.10.2022
AT26.10.2022
CZ26.10.2022
DK26.10.2022
EE26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
MC26.10.2022
NL26.10.2022
PL26.10.2022
RO26.10.2022
RS26.10.2022
SE26.10.2022
SI26.10.2022
SK26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
[2024/28]
Former [2023/51]AL26.10.2022
AT26.10.2022
CZ26.10.2022
DK26.10.2022
EE26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
PL26.10.2022
RO26.10.2022
RS26.10.2022
SE26.10.2022
SI26.10.2022
SK26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
Former [2023/38]AL26.10.2022
AT26.10.2022
CZ26.10.2022
DK26.10.2022
EE26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
PL26.10.2022
RO26.10.2022
RS26.10.2022
SE26.10.2022
SK26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
Former [2023/37]AL26.10.2022
AT26.10.2022
CZ26.10.2022
DK26.10.2022
EE26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
PL26.10.2022
RO26.10.2022
RS26.10.2022
SE26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
Former [2023/35]AT26.10.2022
CZ26.10.2022
DK26.10.2022
EE26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
PL26.10.2022
RO26.10.2022
RS26.10.2022
SE26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
Former [2023/34]AT26.10.2022
DK26.10.2022
EE26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
PL26.10.2022
RS26.10.2022
SE26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
Former [2023/33]AT26.10.2022
DK26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
PL26.10.2022
RS26.10.2022
SE26.10.2022
SM26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
Former [2023/26]AT26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
PL26.10.2022
RS26.10.2022
SE26.10.2022
NO26.01.2023
GR27.01.2023
IS26.02.2023
PT27.02.2023
Former [2023/24]AT26.10.2022
FI26.10.2022
HR26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
SE26.10.2022
NO26.01.2023
GR27.01.2023
PT27.02.2023
Former [2023/23]AT26.10.2022
FI26.10.2022
LT26.10.2022
LV26.10.2022
NL26.10.2022
SE26.10.2022
NO26.01.2023
GR27.01.2023
PT27.02.2023
Former [2023/22]AT26.10.2022
FI26.10.2022
LT26.10.2022
NL26.10.2022
SE26.10.2022
NO26.01.2023
PT27.02.2023
Former [2023/20]LT26.10.2022
NL26.10.2022
NO26.01.2023
Former [2023/17]NL26.10.2022
Documents cited:Search[X]WO2009126662  (SYNDAX PHARMACEUTICALS INC [US], et al) [X] 1,2,10 * claims 1, 18, 26 *;
 [A]  - SADEGHI N ET AL, "Targeting the PI3K pathway for cancer therapy", FUTURE MEDICINAL CHEMISTRY, FUTURE SCIENCE LTD, GB, (20120601), vol. 4, no. 9, doi:10.4155/FMC.12.56, ISSN 1756-8919, pages 1153 - 1169, XP008166436 [A] 3,9 * the whole document *

DOI:   http://dx.doi.org/10.4155/fmc.12.56
International search[X]WO2008076447  (ORDWAY RES INST [US], et al);
 [X]US2008182865  (WITTA SAMIR E [US], et al);
 [Y]WO2011091213  (ACETYLON PHARMACEUTICALS [US], et al);
 [Y]WO2012068109  (ACETYLON PHARMACEUTICALS [US], et al);
 [Y]  - TURKE, ALEXA B., "PIKing the right patient.", CLIN CANCER RES., vol. 16, no. 14, (20100715), pages 3523 - 3525, URL: http:// www.aacrjournals.org>, XP055333052

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-10-1201
 [Y]  - RAHMANI, MOHAMED ET AL., "Inhibition of PI-3 kinase sensitizes human leukemic cells to histone deacetylase inhibitor-mediated apoptosis through p44/42 MAP kinase inactivation and abrogation of p21 CIP1/WAF1 induction rather than AKT inhibition.", ONCOGENE, (2003), vol. 22, pages 6231 - 6242, XP055269982

DOI:   http://dx.doi.org/10.1038/sj.onc.1206646
 [Y]  - ALDANA-MASANGKAY, G.I. ET AL., "The role of HDAC6 in cancer''.", J. BIOMED. BIOTECHNOL., (2011), page 875824, XP055333054

DOI:   http://dx.doi.org/10.1155/2011/875824
Examination   - C. Qian ET AL, "Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling", Clinical Cancer Research, US, (20120801), vol. 18, no. 15, doi:10.1158/1078-0432.CCR-12-0055, ISSN 1078-0432, pages 4104 - 4113, XP055350521

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-12-0055
by applicantUS2008182865
 WO2009126662
    - "Targeting the PI3K pathway for cancer therapy", SADEGHI N et al., Future Medicinal Chemistry, Future Science Ltd, (20120601), vol. 4, pages 1153 - 1169
    - Remington's Pharmaceutical Sciences, Mack Publishing Company, (19900000), page 1418
    - Journal of Pharmaceutical Science, (19770000), vol. 66, page 2
    - HOLFORD, N. H. G.SCHEINER, L. B., Clin. Pharmacokinet., (19810000), vol. 6, pages 429 - 453
    - LOEWE, S.MUISCHNEK, H., Arch. Exp. Pathol Pharmacol., (19260000), vol. 114, pages 313 - 326
    - CHOU, T. C.TALALAY, P., Adv. Enzyme Regul., (19840000), vol. 22, pages 27 - 55
 WO2011US21982
 WO2011US60791
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.